Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

ABSTRACT: Immune checkpoint blockade has led to paradigm shifts in the treatment of various tumour types^1-4, yet limited efficacy has been observed in patients with metastatic mismatch-repair-proficient (pMMR) colorectal cancer⁵. Here we report clinical results and in-depth analysis of patients with early-stage pMMR colon cancer from the phase II NICHE study (ClinicalTrials.gov: NCT03026140). A total of 31 patients received neoadjuvant treatment of nivolumab plus ipilimumab followed by surgery. The response rate was 26% and included six patients with a major pathological response (10% or less residual viable tumour). One patient with an ongoing clinical complete response did not undergo surgery. Circulating tumour DNA was positive in 26 of 31 patients at baseline, and clearance

SUBMITTER: Tan PB 

PROVIDER: S-EPMC12711568 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature